— Know what they know.
Not Investment Advice

SONN NASDAQ

Sonnet BioTherapeutics Holdings, Inc.
1W: -74.0% 1M: -74.9% 3M: -59.7% 1Y: -52.1% 3Y: -99.3% 5Y: -100.0%
$1.26
Last traded 2025-12-02 — delisted
NASDAQ · Healthcare · Biotechnology · $8.4M mcap · 7M float · 16.75% daily turnover · Short 69% of daily vol

Balance Sheet Trends

Total Assets
$15M +437.1% ▲
5Y CAGR: +13.2%
Total Liabilities
$4M +25.8% ▲
5Y CAGR: -3.8%
Shareholders Equity
$11M +2320.9% ▲
5Y CAGR: +29.0%
Cash & Investments
$5M +3325.9% ▲
5Y CAGR: -7.0%
Total Debt
$47K -64.4% ▼
5Y CAGR: -33.3%
Net Debt
-$5M -27189.6% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$28M$3M$2M$149K$5M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$28M$3M$2M$149K$5M
Net Receivables$0$717K$787K$762K$0
Inventory$0$0$0$0$0
Other Current Assets$0-$717K$2M$0$9M
Total Current Assets$29M$5M$5M$2M$14M
Property, Plant & Equip.$182K$303K$227K$144K$55K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$113K$464K$509K$487K
Total Non-Current Assets$182K$416K$691K$653K$542K
Total Assets$29M$6M$5M$3M$15M
— Liabilities —
Accounts Payable$4M$5M$2M$2M$3M
Short-Term Debt$748$748$73K$0$47K
Deferred Revenue$516K$166K$19K$0$0
Other Current Liabilities$1M$2M$1M$152K$1M
Total Current Liabilities$7M$8M$6M$3M$4M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$31K$204K$131K$47K$0
Total Liabilities$7M$8M$6M$3M$4M
— Equity —
Common Stock$6K$554$175$65$708
Retained Earnings-$62M-$91M-$110M-$118M-$134M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$22M-$3M-$226K-$486K$11M
Total Liabilities & Equity$29M$6M$5M$3M$15M
— Key Metrics —
Total Debt$126K$256K$204K$131K$47K
Net Debt-$27M-$3M-$2M-$19K-$5M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms